Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma

OncoImmunology

Volumn 5, Issue 9, 2016, Pages

  Granzin, Markus ^a,b   Stojanovic, Ana ^a   Miller, Matthias ^a   Childs, Richard ^c   Huppert, Volker ^b   Cerwenka, Adelheid ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MILTENYI BIOTEC GMBH   (Germany)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cancer immunotherapy; EBV LCL; Interleukin 21; melanoma; Natural killer cells; NK cell expansion; xenograft mouse model

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 21; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY ASSAY; DEGRANULATION; FEEDER CELL; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; TUMOR GROWTH; TUMOR NECROSIS;

EID: 84987899128     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1219007     Document Type: Article

References (34)

1. M.Cheng, Y.Chen, W.Xiao, R.Sun, Z.Tian. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013; 10:230-52; PMID:23604045; http://dx.doi.org/10.1038/cmi.2013.10
2. J.E.Rubnitz, H.Inaba, R.C.Ribeiro, S.Pounds, B.Rooney, T.Bell, C.-H.Pui, W.Leung. NKAML:a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28:955-9; PMID:20085940; http://dx.doi.org/10.1200/JCO.2009.24.4590
3. H.G.Klingemann. Cellular therapy of cancer with natural killer cells-where do we stand? Cytotherapy 2013; 15:1185-94; PMID:23768925; http://dx.doi.org/10.1016/j.jcyt.2013.03.011
4. U.Koehl, J.Sörensen, R.Esser, S.Zimmermann, H.P.Grüttner, T.Tonn, C.Seidl, E.Seifried, T.Klingebiel, D.Schwabe. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 2004; 33:261-6; PMID:15528141; http://dx.doi.org/10.1016/j.bcmd.2004.08.013
5. H.G.Klingemann, J.Martinson. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy 2004; 6:15-22; PMID:14985163; http://dx.doi.org/10.1080/14653240310004548
6. M.Berg, A.Lundqvist, P.McCoyJr, L.Samsel, Y.Fan, A.Tawab, R.Childs. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11:341-55; PMID:19308771; http://dx.doi.org/10.1080/14653240902807034
7. M.Granzin, S.Soltenborn, S.Müller, J.Kollet, M.Berg, A.Cerwenka, R.W.Childs, V.Huppert. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy 2015; 17:621-32; PMID:25881519; http://dx.doi.org/10.1016/j.jcyt.2015.03.611
8. R.W.Childs, M.Berg. Bringing natural killer cells to the clinic:ex vivo manipulation. Hematology Am Soc Hematol Educ Program 2013; 2013:234-46; PMID:24319186; http://dx.doi.org/10.1182/asheducation-2013.1.234
9. C.J.Denman, V.V.Senyukov, S.S.Somanchi, P.V.Phatarpekar, L.M.Kopp, J.L.Johnson, H.Singh, L.Hurton, S.N.Maiti, M.H.Huls et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 2012; 7:e30264; PMID:22279576; http://dx.doi.org/10.1371/journal.pone.0030264
10. J.Parrish-novak, S.R.Dillon, A.Nelson, A.Hammond, C.Sprecher, J.A.Gross, J.Johnston, K.Madden, W.Xu, J.West et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000; 408:57-63; PMID:11081504; http://dx.doi.org/10.1038/35040504
11. M.R.Davis, Z.Zhu, D.M.Hansen, Q.Bai, Y.Fang. The role of IL-21 in immunity and cancer. Cancer Lett 2015; 358:107-14; PMID:25575696; http://dx.doi.org/10.1016/j.canlet.2014.12.047
12. M.T.Kasaian, M.J.Whitters, L.L.Carter, L.D.Lowe, J.M.Jussif, B.Deng, K.A.Johnson, J.S.Witek, M.Senices, R.F.Konz et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation:A mediator of the transition from innate to adaptive immunity. Immunity 2002; 16:559-69; PMID:11970879; http://dx.doi.org/10.1016/S1074-7613(02)00295-9
13. J.Brady, Y.Hayakawa, M.J.Smyth, S.L.Nutt. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004; 172:2048-58; PMID:14764669; http://dx.doi.org/10.4049/jimmunol.172.4.2048
14. K.Wendt, E.Wilk, S.Buyny, R.E.Schmidt, R.Jacobs. Interleukin-21 differentially affects human natural killer cell subsets. Immunology 2007; 122:486-95; PMID:17635612; http://dx.doi.org/10.1111/j.1365-2567.2007.02675.x
15. N.Strbo, L.de Armas, H.Liu, M.A.Kolber, M.Lichtenheld, S.Pahwa. IL-21 augments natural killer effector functions in chronically HIV-infected individuals. AIDS 2008; 22:1551-60; PMID:18670213; http://dx.doi.org/10.1097/QAD.0b013e3283089367
16. D.P.Lim, Y.Y.Jang, S.Kim, S.S.Koh, J.J.Lee, J.S.Kim, M.T.Thi Phan, D.J.Shin, M.G.Shin, S.H.Lee et al. Effect of exposure to interleukin-21 at various time points on human natural killer cell culture. Cytotherapy 2014; 16:1419-30; PMID:24950680; http://dx.doi.org/10.1016/j.jcyt.2014.04.008
17. Q.Li, L.-J.Ye, H.-L.Ren, T.Huyan, J.Li, J.-L.Shi, Q.-S.Huang. Multiple effects of IL-21 on human NK cells in ex vivo expansion. Immunobiology 2015; 220:876-88; PMID:25758713; http://dx.doi.org/10.1016/j.imbio.2015.01.009
18. W.Leung. Infusions of allogeneic natural killer cells as cancer therapy. Clin Cancer Res 2014; 20:3390-400; PMID:24987108; http://dx.doi.org/10.1158/1078-0432.CCR-13-1766
19. Y.K.Tam, B.Miyagawa, V.C.Ho, H.G.Klingemann. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 1999; 8:281-90; PMID:10417052; http://dx.doi.org/10.1089/106161299320316
20. S.Arai, R.Meagher, M.Swearingen, H.Myint, E.Rich, J.Martinson, H.Klingemann. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma:a phase I trial. Cytotherapy 2008; 10:625-32; PMID:18836917; http://dx.doi.org/10.1080/14653240802301872
21. R.W.Childs, M.Carlsten. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer:the force awakens. Nat Rev Drug Discov 2015; 14:487-98; PMID:26000725; http://dx.doi.org/10.1038/nrd4506
22. J.Ni, M.Miller, A.Stojanovic, A.Cerwenka. Toward the next generation of NK cell-based adoptive cancer immunotherapy. Oncoimmunology 2013; 2:e23811; PMID:23734329; http://dx.doi.org/10.4161/onci.23811
23. S.Szmania, N.Lapteva, T.Garg, A.Greenway, J.Lingo, B.Nair, K.Stone, E.Woods, J.Khan, J.Stivers et al. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother 2015; 38:24-36; PMID:25415285; http://dx.doi.org/10.1097/CJI.0000000000000059
24. J.S.Miller, Y.Soignier, A.Panoskaltsis-Mortari, S.A.McNearney, G.H.Yun, S.K.Fautsch, D.McKenna, C.Le, T.E.Defor, L.J.Burns et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-7; PMID:15632206; http://dx.doi.org/10.1182/blood-2004-07-2974
25. M.A.Geller, S.Cooley, P.L.Judson, R.Ghebre, L.F.Carson, P.A.Argenta, A.L.Jonson, A.Panoskaltsis-Mortari, J.Cursinger, D.McKenna et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13:98-107; PMID:20849361; http://dx.doi.org/10.3109/14653249.2010.515582
26. J.S.Miller, C.M.Rooney, J.Curtsinger, R.McElmurry, V.McCullar, M.R.Verneris, N.Lapteva, D.McKenna, J.E.Wagner, B.R.Blazar et al. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration:implications for clinical therapy. Biol Blood Marrow Transplant 2014; 20:1252-7; PMID:24816582; http://dx.doi.org/10.1016/j.bbmt.2014.05.004
27. H.Zhang, K.S.Chua, M.Guimond, V.Kapoor, M.V.Brown, T.A.Fleisher, L.M.Long, D.Bernstein, B.J.Hill, D.C.Douek et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005; 11:1238-43; PMID:16227988; http://dx.doi.org/10.1038/nm1312
28. V.Bachanova, L.J.Burns, D.H.McKenna, J.Curtsinger, A.Panoskaltsis-Mortari, B.R.Lindgren, S.Cooley, D.Weisdorf, J.S.Miller. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 2010; 59:1739-44; PMID:20680271; http://dx.doi.org/10.1007/s00262-010-0896-z
29. S.Nayar, P.Dasgupta, C.Galustian. Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies–A review. Oncoimmunology 2015; 4:e1002720; PMID:26155387; http://dx.doi.org/10.1080/2162402X.2014.1002720
30. H.Klingemann. Are natural killer cells superior CAR drivers? Oncoimmunology 2014; 3:e28147; PMID:25340009; http://dx.doi.org/10.4161/onci.28147
31. M.Salagianni, C.N.Baxevanis, M.Papamichail, S.A.Perez. New insights into the role of NK cells in cancer immunotherapy. Oncoimmunology 2012; 1:205-7; PMID:22720243; http://dx.doi.org/10.4161/onci.1.2.18398
32. H.Braumüller, T.Wieder, E.Brenner, S.Aßmann, M.Hahn, M.Alkhaled, K.Schilbach, F.Essmann, M.Kneilling, C.Griessinger et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494:361-5; PMID:23376950; http://dx.doi.org/10.1038/nature11824
33. B.Zhang, T.Karrison, D.A.Rowley. Schreiber H. IFN-γ- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 2008; 118:1398-404; PMID:18317595; http://dx.doi.org/10.1172/JCI33522
34. J.Ni, M.Miller, A.Stojanovic, N.Garbi, A.Cerwenka. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 2012; 209:2351-65; PMID:23209317; http://dx.doi.org/10.1084/jem.20120944